AbbVie Inc (ABBV)vsSotera Health Co (SHC)
ABBV
AbbVie Inc
$234.89
+0.06%
HEALTHCARE · Cap: $391.50B
SHC
Sotera Health Co
$15.74
+0.32%
HEALTHCARE · Cap: $4.62B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5183% more annual revenue ($62.82B vs $1.19B). SHC leads profitability with a 9.9% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.61. SHC earns a higher WallStSmart Score of 68/100 (B-).
ABBV
Buy63
out of 100
Grade: C+
SHC
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$234.89
$88.67 premium
Intrinsic value data unavailable for SHC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Strong operational efficiency at 31.3%
Earnings expanding 175.4% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : SHC
The strongest argument for SHC centers on Operating Margin, EPS Growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : SHC
The primary concerns for SHC are PEG Ratio, P/E Ratio, Free Cash Flow. Debt-to-equity of 3.65 is elevated, increasing financial risk.
Key Dynamics to Monitor
SHC carries more volatility with a beta of 1.80 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SHC scores higher overall (68/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sotera Health Co
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Sotera Health Company provides sterilization, laboratory testing, and advisory services to the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company is headquartered in Broadview Heights, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?